Vitamin K Status Based on K1, MK-4, MK-7, and Undercarboxylated Prothrombin Levels in Adolescent and Adult Patients with Cystic Fibrosis: A Cross-Sectional Study

Overview

Journal Nutrients

Date 2024 May 11

PMID 38732584

Authors

Patrycja Krzyzanowska-Jankowska

Jan Nowak

Marta Karazniewicz-Lada

Malgorzata Jamka

Eva Klapkova

Szymon Kurek

Slawomira Drzymala-Czyz

Aleksandra Lisowska

Irena Wojsyk-Banaszak

Wojciech Skorupa

Jaroslaw Szydlowski

Richard Prusa

Jaroslaw Walkowiak

Affiliations

Soon will be listed here.

Abstract

The available evidence on vitamin K status in cystic fibrosis (CF) is scarce, lacking data on vitamin K2 (menaquinones-MK). Therefore, we assessed vitamin K1, MK-4 and MK-7 concentrations (LC-MS/MS) in 63 pancreatic insufficient and modulator naïve CF patients, and compared to 61 healthy subjects (HS). Vitamin K1 levels did not differ between studied groups. MK-4 concentrations were higher (median <1st-3rd quartile>: 0.778 <0.589-1.086> vs. 0.349 <0.256-0.469>, < 0.0001) and MK-7 levels lower (0.150 <0.094-0.259> vs. 0.231 <0.191-0.315>, = 0.0007) in CF patients than in HS. MK-7 concentrations were higher in CF patients receiving K1 and MK-7 supplementation than in those receiving vitamin K1 alone or no supplementation. Moreover, vitamin K1 concentrations depended on the supplementation regime. Based on multivariate logistic regression analysis, we have found that MK-7 supplementation dose has been the only predictive factor for MK-7 levels. In conclusion, vitamin K1 levels in CF are low if not currently supplemented. MK-4 concentrations in CF patients supplemented with large doses of vitamin K1 are higher than in HS. MK-7 levels in CF subjects not receiving MK-7 supplementation, with no regard to vitamin K1 supplementation, are low. There do not seem to be any good clinical predictive factors for vitamin K status.

References

Maqbool A, Stallings V . Update on fat-soluble vitamins in cystic fibrosis. Curr Opin Pulm Med. 2008; 14(6):574-81. DOI: 10.1097/MCP.0b013e3283136787. View

Okano T, Shimomura Y, Yamane M, Suhara Y, Kamao M, Sugiura M . Conversion of phylloquinone (Vitamin K1) into menaquinone-4 (Vitamin K2) in mice: two possible routes for menaquinone-4 accumulation in cerebra of mice. J Biol Chem. 2007; 283(17):11270-9. DOI: 10.1074/jbc.M702971200. View

Sinaasappel M, Stern M, Littlewood J, Wolfe S, Steinkamp G, Heijerman H . Nutrition in patients with cystic fibrosis: a European Consensus. J Cyst Fibros. 2004; 1(2):51-75. DOI: 10.1016/s1569-1993(02)00032-2. View

Nicolaidou P, Stavrinadis I, Loukou I, Papadopoulou A, Georgouli H, Douros K . The effect of vitamin K supplementation on biochemical markers of bone formation in children and adolescents with cystic fibrosis. Eur J Pediatr. 2006; 165(8):540-5. DOI: 10.1007/s00431-006-0132-1. View

Knapen M, Braam L, Drummen N, Bekers O, Hoeks A, Vermeer C . Menaquinone-7 supplementation improves arterial stiffness in healthy postmenopausal women. A double-blind randomised clinical trial. Thromb Haemost. 2015; 113(5):1135-44. DOI: 10.1160/TH14-08-0675. View

Walkowiak J . Assessment of maldigestion in cystic fibrosis. J Pediatr. 2004; 145(3):285-7. DOI: 10.1016/j.jpeds.2004.06.033. View

Bergeron C, Potter K, Boudreau V, Ouliass B, Bonhoure A, Lacombe J . Low vitamin K status in adults with cystic fibrosis is associated with reduced body mass index, insulin secretion, and increased pseudomonal colonization. Appl Physiol Nutr Metab. 2023; 48(4):321-330. DOI: 10.1139/apnm-2022-0163. View

Xia J, Matsuhashi S, Hamajima H, Iwane S, Takahashi H, Eguchi Y . The role of PKC isoforms in the inhibition of NF-κB activation by vitamin K2 in human hepatocellular carcinoma cells. J Nutr Biochem. 2012; 23(12):1668-75. DOI: 10.1016/j.jnutbio.2011.11.010. View

Conway S . Vitamin K in cystic fibrosis. J R Soc Med. 2004; 97 Suppl 44:48-51. PMC: 1308799. View

10.

Hadipour E, Tayarani-Najaran Z, Fereidoni M . Vitamin K2 protects PC12 cells against Aβ and HO-induced apoptosis via p38 MAP kinase pathway. Nutr Neurosci. 2018; 23(5):343-352. DOI: 10.1080/1028415X.2018.1504428. View

11.

Abdel-Rahman M, Alkady E, Ahmed S . Menaquinone-7 as a novel pharmacological therapy in the treatment of rheumatoid arthritis: A clinical study. Eur J Pharmacol. 2015; 761:273-8. DOI: 10.1016/j.ejphar.2015.06.014. View

12.

Miyazawa K, Yaguchi M, Funato K, Gotoh A, Kawanishi Y, Nishizawa Y . Apoptosis/differentiation-inducing effects of vitamin K2 on HL-60 cells: dichotomous nature of vitamin K2 in leukemia cells. Leukemia. 2001; 15(7):1111-7. DOI: 10.1038/sj.leu.2402155. View

13.

Castellani C, Southern K, Brownlee K, Dankert Roelse J, Duff A, Farrell M . European best practice guidelines for cystic fibrosis neonatal screening. J Cyst Fibros. 2009; 8(3):153-73. DOI: 10.1016/j.jcf.2009.01.004. View

14.

Showalter S, Wang Z, Costantino C, Witkiewicz A, Yeo C, Brody J . Naturally occurring K vitamins inhibit pancreatic cancer cell survival through a caspase-dependent pathway. J Gastroenterol Hepatol. 2009; 25(4):738-44. DOI: 10.1111/j.1440-1746.2009.06085.x. View

15.

Ronn S, Harslof T, Pedersen S, Langdahl B . Vitamin K2 (menaquinone-7) prevents age-related deterioration of trabecular bone microarchitecture at the tibia in postmenopausal women. Eur J Endocrinol. 2016; 175(6):541-549. DOI: 10.1530/EJE-16-0498. View

16.

Sokol R, Durie P . Recommendations for management of liver and biliary tract disease in cystic fibrosis. Cystic Fibrosis Foundation Hepatobiliary Disease Consensus Group. J Pediatr Gastroenterol Nutr. 1999; 28 Suppl 1:S1-13. DOI: 10.1097/00005176-199900001-00001. View

17.

Caluwe R, Vandecasteele S, Van Vlem B, Vermeer C, De Vriese A . Vitamin K2 supplementation in haemodialysis patients: a randomized dose-finding study. Nephrol Dial Transplant. 2013; 29(7):1385-90. DOI: 10.1093/ndt/gft464. View

18.

Eelderink C, Kremer D, Riphagen I, Knobbe T, Schurgers L, Pasch A . Effect of vitamin K supplementation on serum calcification propensity and arterial stiffness in vitamin K-deficient kidney transplant recipients: A double-blind, randomized, placebo-controlled clinical trial. Am J Transplant. 2023; 23(4):520-530. DOI: 10.1016/j.ajt.2022.12.015. View

19.

Borowitz D, Baker R, Stallings V . Consensus report on nutrition for pediatric patients with cystic fibrosis. J Pediatr Gastroenterol Nutr. 2002; 35(3):246-59. DOI: 10.1097/00005176-200209000-00004. View

20.

Konieczna L, Kazmierska K, Roszkowska A, Szlagatys-Sidorkiewicz A, Baczek T . The LC-MS method for the simultaneous analysis of selected fat-soluble vitamins and their metabolites in serum samples obtained from pediatric patients with cystic fibrosis. J Pharm Biomed Anal. 2016; 124:374-381. DOI: 10.1016/j.jpba.2016.03.021. View